Iovance Biotherapeutics's Total Assets for the quarter that ended in Mar. 2024 was $869.83 Mil.
During the past 12 months, Iovance Biotherapeutics's average Total Assets Growth Rate was 158.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 53.30% per year.
During the past 5 years, the average Total Assets Growth Rate was 99.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 108.60% per year.
During the past 13 years, Iovance Biotherapeutics's highest 3-Year average Total Assets Growth Rate was 306.90%. The lowest was 7.20%. And the median was 140.50%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Iovance Biotherapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iovance Biotherapeutics (NAS:IOVA) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Iovance Biotherapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Iovance Biotherapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Iovance Biotherapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Iovance Biotherapeutics (Iovance Biotherapeutics) Business Description
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IOVA has been successfully added to your 